Clinical Trial Update: Intravesical Gem/Doce in Patients With NMIBC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating intravesical gemcitabine and docetaxel for non-muscle invasive bladder cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• Taxotere (docetaxel)

Snippet

Sponsor: University of Arizona | Conditions: Urinary Bladder Cancer | Phase 2 | Status: RECRUITING